Application of FXR antagonist in preparing anti-HBV medicines

An antagonist and antiviral drug technology, applied in the field of new drug research and development, can solve problems such as drug resistance and HBV replication rebound, and achieve the effects of reducing economic burden, improving liver function, and promoting HBV clearance.

Inactive Publication Date: 2017-12-08
HENAN UNIVERSITY
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although nucleoside (acid) analogs can quickly inhibit the virus, they often

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FXR antagonist in preparing anti-HBV medicines
  • Application of FXR antagonist in preparing anti-HBV medicines
  • Application of FXR antagonist in preparing anti-HBV medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] CDCA (chenodeoxycholic acid) promotes HBV expression through FXR in cell models:

[0020] Experimental materials: HepG2, pHBV1.3, pFXR, pGFP, HBV detection kit (Shanghai Kehua), CDCA (Sigma).

[0021] Experimental method: In HepG2 cells, co-transfect pHBV1.3, pFXR plasmid or pGFP control plasmid, 24 hours after transfection, observe the transfection efficiency with a fluorescence microscope, then add CDCA to stimulate for 24 hours and 48 hours, collect the supernatant, ELISA detection of HBeAg expression. Specifically include the following steps:

[0022] ①Equilibrate the kit at room temperature for 30 minutes;

[0023] ② Take the cell supernatant, add 50 μl to each well, and set 2 wells each for the negative control and positive control, and 1 well for the blank control;

[0024] ③ Add 50 μl of enzyme conjugate to each well (not add to the blank well), mix well, and seal the plate;

[0025] ④ Incubate in a 37°C incubator for 1 hour;

[0026] ⑤ Pour off the liquid,...

Embodiment 2

[0031] In cell models, interfering with FXR expression inhibited HBeAg expression instead:

[0032] Experimental materials: HepG2, pHBV1.3, siRNA FXR (Guangzhou Ruibo), CDCA (Sigma), HBV detection kit (Shanghai Kehua).

[0033] Experimental method: In HepG2 cells, pHBV1.3 and siRNA FXR were co-transfected, 24 hours after transfection, then stimulated with CDCA for 48 hours, the supernatant was collected, and the expression of HBeAg was detected by ELISA.

[0034] The experimental result of embodiment 2 is as figure 2 , in the HepG2 cell line, pHBV1.3 and FXR siRNA were co-transfected, CDCA was added 24 hours after transfection, and the supernatant was taken 48 hours after the addition of the drug, and the expression of HBeAg was detected by ELISA. Interference with FXR expression inhibited HBeAg expression instead (P< 0.05).

Embodiment 3

[0036] FXR Regulates HBV Expression in HBV Mouse Model

[0037] Experimental material: FXR - / - Mice (purchased from Jackson Laboratory, USA), C57BL / 6J mice (Beijing Weitong Lihua), pHBV1.3, HBV detection kit (Shanghai Kehua).

[0038] experimental method:

[0039] The HBV replication model was established by injecting HBV clones into the high-pressure tail vein: the tail was sterilized with 75% alcohol, and then irradiated with infrared light to cause varicose veins in the mouse tail, which were clearly visible. Insert the needle parallel to the tail vein, inject 8-10% of the liquid, and finish the injection within 5-8 seconds. Blood was collected on the 1st, 7th, and 14th day after the injection, and 150 μl of 1% pentobarbital sodium was injected intraperitoneally. Incubate at 37°C for 1 hour, then centrifuge at 8000rpm for 10 minutes, and store the separated serum at -80°C. ELISA detects serum HBeAg level, and the test results are as follows: image 3 , FXR expression l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

According to the invention, a farnesoid X receptor (FXR) antagonist is applied to treatment of HBV infected persons. Serum bile acid in the HBV infected persons can promote HBV replication and expression through the FXR, and the FXR receptor antagonist can inhibit the HBV replication and expression, promote HBV cleaning, improve hepatic functions, inhibit hepatic fibrosis and hepatic cirrhosis and reduce risk of metastasis of liver cancer.

Description

technical field [0001] The invention relates to the field of research and development of new drugs, specifically the use of farnesoid derivative X receptor (farnesoid Xreceptor, FXR) antagonists for treating HBV infection, inhibiting HBV replication and expression, promoting HBV clearance, improving liver function, reducing the risk of liver cancer transformation, etc. aspects of application. Background technique [0002] Hepatitis B virus infection is still a global public health problem, and it is closely related to the occurrence of human chronic hepatitis, liver fibrosis, liver cirrhosis, liver ground glass disease and liver cancer. At present, 2 billion people in the world have been infected by HBV, and about 350 million people have become chronically infected. The number of people who die from chronic hepatitis, cirrhosis and liver cancer every year is between 500,000 and 1.2 million, accounting for the tenth cause of death. HBV is a 3.2kb partially double-stranded DN...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/57A61K45/06A61P31/20A61P1/16
CPCA61K31/57A61K45/06
Inventor 陈卫东周云王艳东聂小博叶文凌周静宜
Owner HENAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap